For the Quarter Ending December 2022
The price of Clarithromycin API had taken an irregular trajectory in the North American region by the conclusion of the fourth quarter of 2022. In the first two months of Q4, prices were observed to be constant in the upper range due to strong market demand sentiments and favorable cost support from the operational side.
Additionally, the supply-demand imbalance and regional inflation contributed to an increase in the price of Clarithromycin API. However, due to low demand and ample supply, prices began to decline later in December as inflation began to reduce. Towards the termination of Q4 2022, the values accessed at USD 261500/MT with an average quarterly inclination of 0.31%.
In the fourth quarter of 2022, the Clarithromycin API market in the Asia Pacific region took a volatile turn. At the beginning of Q4 2022, rising end-user sector demand, a number of logistical difficulties, and rising inflation influenced the prices to increase till the second month of the quarter. The strict zero covid regulations and frequent lockdowns in the Chinese regions due to the pandemic resurgence have influenced the market. Rising production costs driven by rising energy prices, as well as increased domestic production to meet demands from both domestic and international markets, kept the market situation competitive. The market remained weak later in December due to low end-user sector demand and enough inventories among the merchants. Towards the termination of Q4 2022, the values accessed at USD 206120/MT with a quarterly inclination of 0.19%.
Prices for Clarithromycin API in the European region showed a see-saw tendency in the fourth quarter of 2022. In the first two months of Q4, the demand for Clarithromycin API in the downstream pharmaceutical industry was seen to be steady. The supply chain was impacted by the continuous port congestion and supply disruption in the European region, which forced an increase in pricing. High freight costs were another factor in Clarithromycin's upward trend. Due to the impending holiday season, European retailers have decided to refill their stocks in large quantities. However, because of existing stocks and declining end-user sector demand in December, prices declined. Towards the end of Q4 2022, the prices of Clarithromycin API were recorded at USD 263660/ton with an average quarterly inclination of 0.06%.
For the Quarter Ending September 2022
By the end of this quarter, Q3 2022, the price of Clarithromycin API had taken an erratic course in the APAC area. Prices were stable in the higher range at the start of the first month of Q3, with sound market demand sentiments and favorable cost support from the operational side. Additionally, the price of Clarithromycin API in the APAC region was impacted by the rising energy cost. Due to enough supplies and a reliable supply chain, prices decreased as September began. Furthermore, the weak market mood was caused by decreased downstream industry demand due to rising inflation. Towards the termination of Q3 222, the values accessed at USD 259280/MT with an average quarterly declination of 0.17%.
By the termination of this quarter Q3 2022, the Clarithromycin API prices witnessed an oscillating trajectory in the APAC region. At the commencement of the first month of Q3, the prices were recorded to be stable on the upper end with sound market demand sentiments with positive cost support from the operational side. Also, the increased energy cost affected the Clarithromycin API prices in the APAC region. Later, with the onset of September, the prices went down significantly owing to enough inventories and a stable supply chain. Furthermore, declining demand from the downstream industry due to surging inflation kept the market sentiments feeble. Towards the termination of Q3 2022, the values accessed at USD 205020/MT with a quarterly declination of 0.27%.
In the third quarter of 2022, the Clarithromycin market decelerated in the European region, owing to a considerable decline in the demand from the downstream pharmaceutical industry. At the onset of the first month of Q3 2022, the prices went stable till the end of the second month owing to sound market sentiments and steady demand from the downstream pharmaceutical industry. Also, stable input costs and regular production rates kept the market sentiments firm. Later, with the commencement of the third month, the prices drop significantly, with extern demand cut down with rising inflation. Furthermore, the stockpile among the domestic manufacturers and suppliers also supported the declining trajectory of Clarithromycin API in the European region. Towards the termination of Q3 2022, the values accessed at USD 263260/MT with an average quarterly declination of 1.33%.
For the Quarter Ending June 2022
The prices of Clarithromycin showcased an escalating behaviour in the North American region. With the commencement of Q2 2022, the Clarithromycin market showed positive market sentiments due to the rise in Covid cases. The prices of raw materials and their derivatives also witnessed record heights. The trade market was affected by ongoing geopolitical tension, with restricted transportation prompting strong market sentiments. Also, increased energy and input costs started a surging price trend in the North American region. Towards the termination of Q2 222, the values accessed at USD 260870/MT with the quarterly inclination of 3.29%.
In the second quarter of 2022, the Clarithromycin market accelerated by the end of Q2 in the APAC region, owing to a considerable reporting of COVID-19 cases and strict lockdown policies imposed in the Asian region. At the onset of the first half of Q2 2022, the prices hiked up with the resurgence of the pandemic and successive increases in Covid cases. With the commencement of the second half of Q2, Clarithromycin witnessed further inclination owing to increasing downstream derivatives and upstream raw material costs in both domestic and overseas markets. Also, high input costs and increased energy prices globally affected clarithromycin prices in Asian countries. Towards the termination of Q2 2022, the values accessed at USD 206870/MT with a quarterly inclination of 6.74%.
By the termination of this quarter Q2, the Clarithromycin API prices witnessed advancement in the European market. In the first half of the quarter, the resurgence of the Covid case slightly affected the market due to a slight increase in the demand from the downstream pharmaceutical industry, eventually affecting the prices of Clarithromycin. Being the importer from Asian countries additionally affected clarithromycin prices owing to suspended shipments and disrupted routes. Towards the end of Q2 2022, a supply crunch and surplus demand affected the prices in the domestic European market. Furthermore, with insufficient inventories and steady demand, the prices increased with maximum cost support. Towards the termination of Q2 2022, the values accessed at USD 287870/MT with a quarterly inclination of 3.69%.